The Ethical Frontier: Navigating Regulatory Scrutiny and Public Acceptance of Germline Editing and its Influence on the Gene Editing Market's Future.
While CRISPR/Cas9 has captured the public imagination and the bulk of recent investment, it is not the only gene editing technology shaping the market. Older technologies, specifically Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs), remain critical components of the therapeutic landscape, holding valuable intellectual property and providing important...
0 Comments 0 Shares 217 Views 0 Reviews